

桃園長庚紀念醫院

抗生素敏感性試驗

2018年報

JAN. ~ DEC.

檢驗醫學科 微生物組

感染管制委員會

製表

GRAM (-) BACILLI

JAN. ~ DEC., 2018

ANTIBIOTICS BACTERIA @	TOTAL (no.)	PERCENT OF SUSCEPTIBILITY**																				
		AM	AMC	AN	CAZ	CIP	CL	CLR	CPS	CRO	CXM	CZ	DOR	ETP	FEP	GM	IPM	LVX	MEM	SAM	SXT	TZP
E. coli	737	-	74	100	73	60	-	-	97	70	69	40	-	99	-	79	-	61	-	67	52	95
Klebsiella pneumoniae	208	-	58	92	70	69	-	-	80	72	64	48	-	84	-	73	-	75	-	64	53	74
Haemophilus influenzae	40	25	76	-	-	-	-	63	-	100	70	-	-	-	-	-	-	-	-	-	33	-
Proteus mirabilis	80	-	88	96	-	76	-	-	100	94	93	38	-	100	-	73	-	84	-	-	51	99
Pseudomonas aeruginosa	164	-	-	99	91	89	100	-	87	-	-	-	93	-	96	94	90	83	90	-	-	87

AMC=amoxicillin/clavulanic acid; AM=ampicillin; AN=amikacin; CAZ=ceftazidime; CIP=ciprofloxacin; CL=colistin; CLR=clarithromycin; CPS=cefoperazone-sulbactam; CRO=ceftriaxone; CXM=cefuroxime; CZ=cefazolin; DOR=doripemun; ETP=ertapenem; FEP=cefepime; GM=gentamicin; IPM=imipenem; LVX=levofloxacin; MEM=meropenem; SAM=ampicillin-sulbactam; SXT=sulfamethoxazole-trimethoprim; TZP=piperacillin-tazobactam; - =not tested or not available

@本年度新上榜的細菌名稱以紅字標示;

*紅字代表細菌數目較去年多10%以上; 藍字代表較去年少10%以上

**紅字代表藥敏性較去年數字低10以上; 藍字代表較去年高10以上

**本表格資料乃統計所有病人在此統計時段內於本院經細菌培養所得第一次藥敏試驗結果, 僅供醫師經驗性選擇抗生素時參考之用; ESBL或PDR菌株均已併入原菌株結果一起檢視.

GRAM (+) BACTERIA

JAN. ~ DEC., 2018

ANTIBIOTICS BACTERIA	TOTAL (no.)*	PERCENT OF SUSCEPTIBILITY**														
		AM	CC	CRO	E	FA	HGM	LVX	LZD	MXF	OX	P	SXT	TEC	TGC	VA
Beta strep. group B	89	100	50	100	54	-	-	-	-	-	-	100	-	100	-	100
Enterococcus faecalis	101	100	-	-	-	-	52	-	-	-	-	99	-	100	-	100
Staphylococcus aureus	241	-	69	-	45	94	-	-	100	-	48	9	90	100	99	100
S. epidermidis	102	-	65	-	43	-	-	-	-	-	31	2	69	100	-	100
Streptococcus pneumoniae	16	-	-	#	-	-	-	100	-	100	-	#	-	-	-	100

AM=ampicillin; CC=clindamycin; CRO=ceftriaxone; E=erythromycin; FA=fusidic acid; HGM= high level gentamicin; LVX=levofloxacin; LZD=linezolid; MXF=moxifloxacin; OX=oxacillin; P=penicillin-G; SXT = sulfamethoxazole-trimethoprim; TEC=teicoplanin; TGC=tigecyclin; VA=vancomycin;

- = not tested or not available

Streptococcus pneumoniae對penicillin與ceftriaxone的藥敏結果綜合整理於最後

*紅字代表細菌數目較去年多10%以上; 藍字代表較去年少10%以上;

**紅字代表藥敏性較去年數字低10以上; 藍字代表較去年高10以上

**本表格資料乃統計所有病人在此統計時段內於本院經細菌培養所得第一次藥敏試驗結果, 僅供醫師經驗性選擇抗生素時參考之用.

Anaerobes

JAN. ~ DEC., 2018

ANTIBIOTICS BACTERIA@	TOTAL (no.)*	PERCENT OF SUSCEPTIBILITY **				
		CC	MET	P	PIP	SAM
Propionibacterium acnes	46	80	0	100	100	100

CC=clindamycin; MET=metronidazole; P=penicillin-G; PIP=piperacillin; SAM = ampicillin-sulbactam

*紅字代表細菌數目較去年多10%以上; 藍字代表較去年少10%以上

**紅字代表藥敏性較去年數字低10以上; 藍字代表較去年高10以上

@本年度新上榜的細菌名稱以紅字標示;

*本表格資料乃統計所有病人在此統計時段內於本院經細菌培養所得
第一次藥敏試驗結果, 僅供醫師經驗性選擇抗生素時參考之用

Streptococcus pneumoniae

JAN.~DEC., 2018

抗生素種類	檢體別	判讀標準	結果分類	全院		
			(濃度範圍,	總菌株數*	菌株數	%**
Penicillin-G	CSF	meningitis標準	S (≤ 0.06)	0	-	-
			-		-	-
			R (≥ 0.12)		-	-
	Other invasive specimens	meningitis標準	S (≤ 0.06)	0	0	0.0
			-		-	-
			R (≥ 0.12)		-	-
		non-meningitis標準	S (≤ 2)		0	0.0
			I (4)		-	-
			R (≥ 8)		-	-
	Non-invasive specimens	non-meningitis標準	S (≤ 2)	14	14	100.0
			I (4)		0	0.0
			R (≥ 8)		0	0.0
Ceftriaxone	CSF	meningitis標準	S (≤ 0.5)	0	-	-
			I (1)		-	-
			R (≥ 2)		-	-
	Other invasive specimens	meningitis標準	S (≤ 0.5)	0	0	0.0
			I (1)		-	-
			R (≥ 2)		-	-
		non-meningitis標準	S (≤ 1)		0	0.0
			I (2)		-	-
			R (≥ 4)		-	-
	Non-invasive specimens	non-meningitis標準	S (≤ 1)	14	11	79.0
			I (2)		3	21.0
			R (≥ 4)		0	0.0

*紅字代表細菌數目較去年多10%以上；藍字代表較去年少10%以上

**紅字代表藥敏性較去年數字低10以上；藍字代表較去年高10以上

GRAM (-) BACILLI - nosocomial isolates only
NOSOCOMIAL ISOLATES ONLY
JAN. ~ DEC.,201601-201812

ANTIBIOTICS BACTERIA	TOTAL (no.)	PERCENT OF SUSCEPTIBILITY**																
		AMC	AN	CAZ	CIP	CPS	CRO	CXM	CZ	DOR	ETP	FEP	GM	IPM	LVX	MEM	SXT	TZP
<i>E. coli</i> ^{&}	84	54	99	-	46	89	42	40	21	-	99	-	83	-	46	-	35	93
<i>Klebsiella pneumoniae</i> ^{&&}	47	55	94	-	57	87	57	49	40	-	83	-	57	-	64	-	48	66
<i>Pseudomonas aeruginosa</i> ^{&&&}	27	-	100	96	96	100	-	-	-	96	-	96	96	96	96	96	-	93

AMC=amoxicillin/clavulanic acid; AN=amikacin; CAZ=ceftazidime; CIP=ciprofloxacin; CPS=cefoperazone-sulbactam; CRO=ceftriaxone; CXM=cefuroxime; CZ=cefazolin; DOR=doripemun; ETP=ertapenem; FEP=cefepime; GM=gentamicin; IPM=imipenem; LVX=levofloxacin; MEM=meropenem; SXT=sulfamethoxazole-trimethoprim; TZP=piperacillin-tazobactam; - =not tested or not available

&上表中所列數字, 已包含CR菌株1株(1.2%)

&&上表中所列數字, 已包含CR及MDR菌株8株(17%)

&&&上表中所列數字, 已包含CR菌株1株(3.7%)

**GRAM (+) BACTERIA
NOSOCOMIAL ISOLATES ONLY
JAN.~ DEC., 201601-201812**

ANTIBIOTICS BACTERIA	TOTAL (no.)	PERCENT OF SUSCEPTIBILITY**											
		AM	CC	E	FA	HGM	LZD	OX	P	SXT	TEC	TGC	VA
<i>Enterococcus faecalis</i>	12	100	-	-	-	33	-	-	75	-	100	-	100
<i>Staphylococcus aureus</i> ^{&}	28	-	80	52	93	-	100	46	4	82	100	100	100

AM=ampicillin; CC=clindamycin; E=erythromycin; FA=fusidic acid; HGM= high level gentamicin; LZD=linezolid;
 OX=oxacillin; P=penicillin-G; SXT = sulfamethoxazole-trimethoprim; TEC=teicoplanin; TGC=tigecyclin; VA=vancomycin;
 - = not tested or not available
 & S. aureus含MRSA 15株 (53.6%)

醫療照護相關菌株
JAN. ~ DEC., 2018

**部位別						
排名	BSI	數量	UTI	數量	SSI	數量
1	Klebsiella pneumoniae	9	E.coli	25	Pseudomonas aeruginosa	2
2	E.coli	5	Klebsiella pneumoniae	12	&	
3	Acinetobacter nosocomialis	3	Yeast-like	4	&	

*前三名分別為E. coli, Klebsiella pneumoniae, Staphylococcus aureus

**感染部位別分析：前三名分別為UTI，BSI, SSI

& 菌株數≤1，不另行列表